Product/Composition:- | Caspofungin Intravenous (IV) Powder |
---|---|
Strength:- | 50 mg/vial, 70 mg/vial |
Form:- | Intravenous (IV) Powder |
Reference Brands:- | Cancidas (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Caspofungin inhibits fungal β-glucan synthase, disrupting fungal cell wall synthesis and causing cell death. It provides broad-spectrum activity against invasive fungi like Candida and Aspergillus. Benefits include rapid action, effectiveness in severe infections, minimal toxicity, and suitability for immunocompromised patients, making it vital for life-threatening fungal diseases.
Caspofungin IV powder is approved in the EU and US for treating invasive fungal infections. In the EU, Merck’s Cancidas is regulated by EMA, supported by dossiers demonstrating safety, efficacy, and manufacturing quality. In the US, FDA approval is based on comprehensive clinical data, biosimilarity assessments, and pharmacovigilance. Both regions require detailed dossiers for initial approval and ongoing safety monitoring. For expert assistance with pharmaceutical dossiers, regulatory submissions, and compliance, visit PharmaTradz. We facilitate efficient market access for caspofungin IV formulations, ensuring adherence to European and American standards for safe, effective antifungal therapy.